WHAT IS CLAIMED IS:

1. A compound according to formula I:



formula I;

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

each R^0 is independently hydrogen or (C1-C3)alkyl;

A is H; and

B is:



,


,


,


,


, or


,

wherein the piperazin-2-yl is substituted with 1, 2, or 3 substituents independently selected from the group consisting of (C2-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)acyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aryl, and heteroaryl;

wherein the 1,4-diazepan-2-yl, 1,4-diazepan-5-yl, 1,4-diazepan-6-yl, 1,4-diazocan-2-yl, or 1,5-diazocan-3-yl is optionally substituted with 1, 2, or 3 substituents independently

o

selected from the group consisting of (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)acyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aryl, and heteroaryl; and

wherein each (C1-C4)alkyl, (C2-C4)alkyl, (C2-C4)alkenyl, and (C2-C4)alkynyl substituent is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, O(C1-C4)alkyl, and SH.

2. The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is:



,


,


,


, or


,

wherein the piperazin-2-yl is substituted with 1, 2, or 3 substituents independently selected from the group consisting of (C2-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)acyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aryl, and heteroaryl;

wherein the 1,4-diazepan-2-yl, 1,4-diazepan-6-yl, 1,4-diazocan-2-yl, or 1,5-diazocan-3-yl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)acyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aryl, and heteroaryl; and

wherein each (C1-C4)alkyl, (C2-C4)alkyl, (C2-C4)alkenyl and (C2-C4)alkynyl substituent is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, O(C1-C4)alkyl, and SH.

o

3. A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition is formulated for oral administration.

5. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition is for parenteral administration.

6. The pharmaceutical composition according to claim 5, wherein the parenteral administration is subcutaneous, intravenous, intramuscular, or intrathecal.

7. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition further comprises an antioxidant.

8. A compound according to formula I:



formula I;

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

each R^0 is independently hydrogen or (C1-C3)alkyl;

A is H; and

o

B is:

 ,  ,  ,  ,  , or

 ,

wherein the piperazin-2-yl, 1,4-diazepan-2-yl, 1,4-diazepan-5-yl, 1,4-diazepan-6-yl, 1,4-diazocan-2-yl, or 1,5-diazocan-3-yl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)acyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aryl, and heteroaryl; and

wherein each (C1-C4)alkyl, (C2-C4)alkenyl, and (C2-C4)alkynyl substituent is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, O(C1-C4)alkyl, and SH.

9. A pharmaceutical composition comprising the compound according to claim 8, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is formulated for oral administration.

o

11. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is formulated for parenteral administration.

12. The pharmaceutical composition according to claim 11, wherein the parenteral administration is subcutaneous, intravenous, intramuscular, or intrathecal.

13. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition further comprises an antioxidant.

14. A compound selected from the group consisting of:



22,


26,


28,


29,


30,


31,


34,


39, and


40, or a pharmaceutically acceptable salt or stereoisomer thereof.

o

15. A pharmaceutical composition comprising the compound according to claim 14, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition is formulated for oral administration.

17. The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition is formulated for parenteral administration.

18. The pharmaceutical composition according to claim 17, wherein the parenteral administration is subcutaneous, intravenous, intramuscular, or intrathecal.

19. The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition further comprises an antioxidant.

20. A compound selected from the group consisting of:



43,



45,



47,



48, and



49, or a

pharmaceutically acceptable salt thereof.

o

21. A pharmaceutical composition comprising the compound according to claim 20, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

22. The pharmaceutical composition according to claim 21, wherein the pharmaceutical composition is formulated for oral administration.

23. The pharmaceutical composition according to claim 21, wherein the pharmaceutical composition is formulated for parenteral administration.

24. The pharmaceutical composition according to claim 23, wherein the parenteral administration is subcutaneous, intravenous, intramuscular, or intrathecal.

25. The pharmaceutical composition according to claim 21, wherein the pharmaceutical composition further comprises an antioxidant.

o